Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Intestinal transit-amplifying cells require METTL3 for growth factor signaling and cell survival
Charles H. Danan, Kaitlyn E. Naughton, Katharina E. Hayer, Sangeevan Vellappan, Emily A. McMillan, Yusen Zhou, Rina Matsuda, Shaneice K. Nettleford, Kay Katada, Louis R. Parham, Xianghui Ma, Afrah Chowdhury, Benjamin J. Wilkins, Premal Shah, Matthew D. Weitzman, Kathryn E. Hamilton
Charles H. Danan, Kaitlyn E. Naughton, Katharina E. Hayer, Sangeevan Vellappan, Emily A. McMillan, Yusen Zhou, Rina Matsuda, Shaneice K. Nettleford, Kay Katada, Louis R. Parham, Xianghui Ma, Afrah Chowdhury, Benjamin J. Wilkins, Premal Shah, Matthew D. Weitzman, Kathryn E. Hamilton
View: Text | PDF
Research Article Gastroenterology

Intestinal transit-amplifying cells require METTL3 for growth factor signaling and cell survival

  • Text
  • PDF
Abstract

Intestinal epithelial transit-amplifying cells are essential stem progenitors required for intestinal homeostasis, but their rapid proliferation renders them vulnerable to DNA damage from radiation and chemotherapy. Despite these cells’ critical roles in intestinal homeostasis and disease, few studies have described genes that are essential to transit-amplifying cell function. We report that RNA methyltransferase-like 3 (METTL3) is required for survival of transit-amplifying cells in the murine small intestine. Transit-amplifying cell death after METTL3 deletion was associated with crypt and villus atrophy, loss of absorptive enterocytes, and uniform wasting and death in METTL3-depleted mice. Sequencing of polysome-bound and methylated RNAs in enteroids and in vivo demonstrated decreased translation of hundreds of methylated transcripts after METTL3 deletion, particularly transcripts involved in growth factor signal transduction such as Kras. Further investigation verified a relationship between METTL3 and Kras methylation and protein levels in vivo. Our study identifies METTL3 as an essential factor supporting the homeostasis of small intestinal tissue via direct maintenance of transit-amplifying cell survival. We highlight the crucial role of RNA modifications in regulating growth factor signaling in the intestine with important implications for both homeostatic tissue renewal and epithelial regeneration.

Authors

Charles H. Danan, Kaitlyn E. Naughton, Katharina E. Hayer, Sangeevan Vellappan, Emily A. McMillan, Yusen Zhou, Rina Matsuda, Shaneice K. Nettleford, Kay Katada, Louis R. Parham, Xianghui Ma, Afrah Chowdhury, Benjamin J. Wilkins, Premal Shah, Matthew D. Weitzman, Kathryn E. Hamilton

×

Figure 5

METTL3 deletion triggers growth arrest and death in intestinal epithelial enteroids and colonoids.

Options: View larger image (or click on image) Download as PowerPoint
METTL3 deletion triggers growth arrest and death in intestinal epithelia...
(A) Intestinal epithelial enteroids or colonoids were treated with 1 μm 4-OHT 48 and 24 hours before beginning of time course and analyzed at days 1 through 5. (B) Percentage live enteroids or colonoids from indicated tissue regions at 5 days after 4-OHT treatment. Each point represents n = 9 technical replicates across n = 3 passage separated biological replicates per genotype. Data presented as median ± SD. P value represents unpaired parametric Student’s t test. (C) Western blot for METTL3 in surviving distal colonoids 6 days after 4-OHT treatment. (D) Representative images at 5 days after 4-OHT treatment corresponding to quantification in B. Scale bar 500 μm. (E and F) ImageJ (NIH) quantification of average enteroid 2D area and percentage live enteroids in each of the 5 days after 4-OHT treatment of Villin-CreERT2 (VilCreERT2) and Mettl3VilCreERΔ/Δ ileal enteroids. Each point represents n = 9 technical replicates across n = 3 passage-separated biological replicates per genotype. Data presented as mean ± SD. P value represents unpaired parametric Student’s t test at day 3 and day 5. (G) Representative images of ileal enteroids in the 5 days after 4-OHT treatment. Scale bar 200 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts